Inhibrx Biosciences, Inc. INBX Payments of Debt Issuance Costs, Secured Debt
Payments of Debt Issuance Costs, Secured Debt at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept inbx:PaymentsOfDebtIssuanceCostsSecuredDebt.
The official record: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s payments of debt issuance costs, secured debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s payments of debt issuance costs, secured debt?
- Inhibrx Biosciences, Inc. (INBX) reported payments of debt issuance costs, secured debt of $31.25K in Q4 2025.
- What does payments of debt issuance costs, secured debt mean?
- This captures the direct cash costs incurred to secure debt financing, such as legal fees, underwriting commissions, and registration expenses. These payments represent the friction costs of raising capital and are typically amortized over the life of the debt instrument. High issuance costs relative to the principal amount can indicate a higher cost of capital or challenging market conditions for the borrower.